AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05802290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 MG in 24 ML Injection
Description: nivolumab monotherapy at 240mg flat dose as a 30-minute IV infusion on Day 1 of a treatment cycle every 2 weeks (14 days) until confirmed progression of disease, unacceptable toxicity, death or withdrawal of consent
Study NCT00603876 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Almonds
Description: 100-110 grams (about 3/4 cupful)of almonds consumed daily for 28 days
Study NCT00506740 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonic scalpel
Description: A surgical instrument that uses ultrasonic energy that allows both cutting and coagulating at the precise point of application.
Study NCT00506740 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: monopolar electrosurgery generator and tip
Study NCT03489538 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic long limb roux-en-Y gastric bypass
Description: standard laparoscopic roux-en-Y gastric bypass (biliopancreatic limb 40 to 60 cm, alimentary limb 150 cm)
Study NCT04684849 — intervention group
Intervention type: OTHER
Intervention: APP Diary
Description: Subjects keep a multi- item electronic digital App survey of symptoms for 2 weeks
Study NCT04684849 — intervention group
Intervention type: OTHER
Intervention: Paper Diary
Description: Subjects keep a multi-item paper survey of symptoms for 2 weeks
Study NCT00060567 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: E7070 + irinotecan combination
Description: Escalating doses starting from 125 mg/m2 irinotecan plus 250 mg/m2 E7070 combination.
Study NCT00060567 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan + E7070 combination
Description: Escalating doses starting from 100 mg/m2 irinotecan plus 400 mg/m2 E7070 combination.
Study NCT01633775 — intervention group
Intervention type: PROCEDURE
Intervention: Implantation of Ahmed glaucoma tube shunt, and Trabeculectomy with MMC
Description: In the Ahmed implant group, the tube shunts used were the valved 184-mm2 surface area (Model FP7; New World Medical, Inc, Rancho Cucamonga, California, USA). In the Trabeculectomy group, a routine trabeculectomy surgery was performed.
Study NCT01805674 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: isoflavones combined with magnolia
Description: 1 tablet/day duration: 12 weeks
Study NCT00517725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carvedilol
Study NCT00517725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bisoprolol
Study NCT00517725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Study NCT01576887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone Methyl 20 mg
Description: Oral, once daily
Study NCT02364427 — intervention group
Intervention type: DEVICE
Intervention: Arterial stiffness - Vicorder to measure pulse wave velocity
Description: Pulse wave velocity (PWV)measures the stiffness of the arteries. This provides a simple and quick noninvasive method of obtaining the PWV for an arterial segment.
Study NCT00351793 — intervention group
Intervention type: DEVICE
Intervention: Knee Implant
Description: Total knee replacement with Genesis II posterior stabilized knee
Study NCT01576887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, once daily
Study NCT01814891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange maize feeding
Description: This group was fed orange maize.
Study NCT01814891 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A supplement
Description: This group received a dose of vitamin A at the estimated average requirement each feeding day of the intervention.
Study NCT01814891 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oil only
Description: This group received a small amount of plain oil without vitamin A.
Study NCT02050672 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myo-inositol
Study NCT02050672 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: untreated
Study NCT02699840 — intervention group
Intervention type: BIOLOGICAL
Intervention: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Description: No vaccine will be provided as part of this study
Study NCT02742155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Play2Sleep
Description: Behavioral: Video self-modelling
Study NCT02742155 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison
Description: Behavioral: Information only
Study NCT00536094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: CBT includes 45-minute psychotherapy sessions once a week for a period of approximately 12 weeks.
Study NCT00536094 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: TAU includes 45-minute psychosocial treatment sessions once a week for a period of approximately 12 weeks.
Study NCT00005066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O6-benzylguanine
Study NCT00005066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Study NCT00086242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Telephone Counseling (PTC)
Description: Eligible patients are randomized to receive psychosocial telephone counseling (PTC) or usual care.The PTC intervention was specifically designed to help women cope with the stressful events and feelings of distress associated with cervical cancer. The PTC arm of the study received six counseling sessions, \~45 to 50 min in length, in their preferred language, consisting of five consecutive weekly sessions and a 1-month booster session, delivered by a psychologist. A review letter, generated by the counselor after each session, recapitulated the session's contents and reinforced adaptive coping strategies.
Study NCT00767494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost/Brinzolamide fixed combination
Description: Eye Drops, suspension once daily
Study NCT00767494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azopt
Description: Eye Drop Suspension, 1 drop BID
Study NCT00767494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travatan
Description: Eye Drop Solution, 1 drop BID
Study NCT03429166 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Training in Affective and Interpersonal Regulation
Description: A non-trauma-focused treatment
Study NCT03429166 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present Centered Therapy
Description: A non-trauma-focused treatment
Study NCT04063540 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amiloride
Description: Treatment by Amiloride vs placebo in crossover
Study NCT04063540 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebos
Description: Treatment by Amiloride vs placebo in crossover
Study NCT01700595 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: new technical intervention
Description: Contractures and broad scars of the subjects are treated by this surgical intervention which is a reconstructive surgery that is performed by the transfer of preexpanded perforator flaps to the recipient sites of skin deficiency.
Study NCT03003013 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biphasic Bone Graft Material (BGM) in Combination With Autologous Platelet-rich Fibrin (PRF)
Study NCT04093895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PerioSept(r)
Description: Scaling and root planing followed by 3% PerioSept(r) administration
Study NCT01634789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bazedoxifene
Description: 20 mg oral tablet, single dose
Study NCT01634789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bazedoxifene/conjugated estrogens
Description: 20 mg / 0.625 mg oral tablet, single dose
Study NCT01855516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Study NCT03980418 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DaTSCAN SPECT/CT in VERITON-CT camera
Description: the intervention is based on two recordings in camera VERITON-CT ; the first, in focus striatum mode and the second in brain focus mode
Study NCT00276939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-fat, low-Glycemic Index, vegan diet
Study NCT00276939 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-fat, low-Glycemic Index, vegan diet
Study NCT01951586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.
Study NCT01951586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zoledronic acid
Description: Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
Study NCT01951586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Denosumab
Description: Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.
Study NCT02052440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Treatment arm: baclofen 10mg tid
Study NCT02052440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill by mouth three times daily
Study NCT02496325 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound guided transperineal pudendal nerve block
Description: Children under general anesthesia were positioned supine, flexed legs and balls of the feet joined. A 12 MegaHertz (MHz) (38 mm) ultrasound probe was positioned on a horizontal axis passing through the ischial tuberosity, previously palpated.The probe was then moved medially on the axis, until the rectum appeared. Pudendal artery was identified if possible, using colour Doppler. The needle (22 Ga, 50 mm) was then introduced at the middle of the superior edge of the probe, in an out-of-plane approach. Tip of the needle was identified by direct vision, through displacement of adjacent anatomical structures or with saline injection. Nerve stimulation was started after placement of the tip of needle in the ischiorectal fossa, before local anaesthetic injection. After a negative aspiration test, a mix of Ropivacaine 2 % and clonidine 0.2µg/kg was injected in the ischiorectal fossa under ultrasound guidance.
Study NCT01951586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Chemotherapy
Description: Standard of care chemotherapy consisting of pemetrexed or gemcitabine in combination with cisplatin or carboplatin administered according to local practice.
Study NCT01951586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard Chemotherapy
Description: Standard of care chemotherapy consisting of pemetrexed or gemcitabine in combination with cisplatin or carboplatin administered according to local practice.
Study NCT01951586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Zoledronic Acid
Description: Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
Study NCT03527836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine brachial plexus block
Description: Combined Axillary-supraclavicular approach to brachial plexus with lidocaine
Study NCT03527836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine brachial plexus block
Description: Combined Axillary-supraclavicular approach to brachial plexus with bupivacaine
Study NCT03527836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mixture brachial plexus block
Description: Combined Axillary-supraclavicular approach to brachial plexus with mixture solution of 20 ml bupivacaine 0.5% and 10 ml lidocaine 1%
Study NCT04368741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SANZ®KINGWILL
Description: 20g nutrition product (SANZ®KINGWILL) was used as extra meal at 10:00am and 15:00pm, respectively.
Study NCT04368741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: GLUCERNA SR®
Description: 17.5g nutrition product (GLUCERNA SR®) was used as extra meal at 10:00am and 15:00pm, respectively.
Study NCT02055742 — intervention group
Intervention type: DEVICE
Intervention: illumigene CT and NG assays, illumipro-10
Study NCT03445364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of different injection pressure during primary PCI
Description: Using ACIST injector during the PCI it is possible to change injection pressure - in one arm low pressure of 200psi, and in the second arm average pressure of 550psi
Study NCT01507935 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular non-hydrolysed cow's milk
Description: Regular non-hydrolysed cow's milk with added prebiotic oligosaccharides mixture I
Study NCT01507935 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular non-hydrolysed cow's milk
Description: Regular non-hydrolysed cow's milk with added prebiotic oligosaccharides mixture II
Study NCT01507935 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular non-hydrolysed cow's milk
Description: Regular non-hydrolysed cow's milk with the same composition as the Investigational Formulas but without supplementation of prebiotic oligosaccharides
Study NCT01368744 — intervention group
Intervention type: DEVICE
Intervention: OSNA Breast Cancer System
Description: For in vitro diagnostic use only.~The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (> 2 mm).~Groups: OSNA Breast Cancer System
Study NCT00976651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human menopausal gonadotropin
Description: 200 IU per day in the late follicular phase
Study NCT00976651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human menopausal gonadotropin
Description: 200 IU per day in the late follicular phase
Study NCT02267902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229
Study NCT02661386 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Motility Procedure
Description: The use of esophageal manometry device during general anesthesia
Study NCT03102827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Patients will receive oxygen with humidified air, fully saturated at 37° C at a flow rate of 20- 50 L/min. The ratio of oxygen and ambient air (FiO2) will be increased stepwise depending on patient's oxygen saturation.
Study NCT03102827 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ambient air without high-flow therapy administered during first night
Study NCT02819258 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Endodontic treatment
Study NCT04116983 — intervention group
Intervention type: DEVICE
Intervention: Deep Ensemble for the Recognition of Malignancy (DERM)
Description: An AI-based diagnosis support tool
Study NCT03043352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Management of SAM at home
Description: LHWs will identify and treat all cases of severe acute malnutrition (SAM) in children under-five years at household level compared with the standard CMAM program
Study NCT03043352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Management of SAM at facility
Description: LHWs will identify SAM as per 'Standard CMAM program' (MUAC \< 11.5cm) and will refer all cases to the health facility BHU/ satellite site (ACF) for further management and counselling by health workers (ACF CMAM Nurse) at facility level.
Study NCT01669252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: 1.23 mg/m2 eribulin ready to use solution (equivalent to 1.4 mg/m2 eribulin mesilate) IV on Days 1 and 8 of every 21-day cycle, for 4 cycles.
Study NCT02978157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole+amox+levo
Description: esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d.
Study NCT02978157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole+bismuth+tetra+levo
Description: esomeprazole 40 mg b.d., bismuth 120 mg q.d.s., tetracycline 500 mg q.d.s., and levofloxacin 500 mg o.d.
Study NCT01508377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure for PTSD with cognitive restructuring
Description: The treatment lasts five weeks. During that time-frame, participants write ten texts for 45 minutes, twice a week. Each time after having received two texts, the therapists provide feedback and further instructions, which are based upon the manual (Lange et al., 2003)~The long version of the PTSD treatment (including cognitive restructuring) can be divided into three phases.~First phase - self-confrontation (4 essays) At the beginning the participants receive psychoeducation about the mechanisms of exposure before writing four essays about their emotionally most painful memories.~Second phase - cognitive restructuring (4 essays) Again the participants write four texts, however, this time they go beyond mere descriptions and use their experiences to write a supportive letter to an imaginary friend who had been through the same experience.~Third phase - parting (2 essays) In the third phase, two texts are written in the form of a letter to document the past in a worthy document.
Study NCT01508377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure for PTSD without cognitive restructuring
Description: The treatment lasts five weeks. During that time-frame, participants write ten texts for approximately 45 minutes, twice a week. Each time after having received two texts, the therapists provide feedback and further instructions, which are based upon the manual (Lange et al., 2003).~The short version of the PTSD treatment can be divided into only two phases. Compared to the long version the phase dealing with cognitive restructuring is excluded.~First phase - self-confrontation (4 essays) At the beginning the participants receive psychoeducation about the mechanisms of exposure before writing four essays about their emotionally most painful memories.~Third phase - parting (2 essays) In the third phase, two texts are written in the form of a letter to document the past in a worthy document.
Study NCT00485758 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ER niacin/laropiprant
Description: One tablet of ER niacin/laropiprant (1g); advancing to ER niacin/laropiprant (2g) at Week 4 for the remainder of the study 36 Weeks.
Study NCT00485758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator : placebo (unspecified)
Description: ER niacin/laropiprant Placebo
Study NCT01206972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY59-7939)
Description: daily dose: 5mg/day (5mg, once daily) for 11 to 12 days (±2 days)
Study NCT01206972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY59-7939)
Description: daily dose: 7.5mg/day (7.5mg, once daily) for 11 to 12 days (±2 days)
Study NCT01206972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY59-7939)
Description: daily dose: 10mg/day (10mg, once daily) for 11 to 12 days (±2 days)
Study NCT01206972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: daily dose: 40mg/day (20mg, twice daily) for 10 to 11 days (±2 days)
Study NCT03508921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Antibiotics
Description: Patients randomized to the Extended Antibiotics arm will receive one dose of trimethoprim/sulfamethoxazole peri-procedurally and additionally be prescribed trimethoprim/sulfamethoxazole twice daily for three days. Patients who are allergic will receive amoxicillin/clavulanic acid (875/125mg) twice daily for three days. If allergic to both of the above antibiotics, patients will receive 100mg nitrofurantoin BID for three days.~For their second injection, they will receive peri-procedural antibiotics only.
Study NCT03508921 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of OnabotulinumtoxinA (BTX-A)
Description: Patients will receive injection of OnabotulinumtoxinA (BTX-A) per standard clinic practice protocol. All patients will undergo injection per a standardized protocol of 1ml injection per site at a concentration of 10 units/ml.
Study NCT00964769 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pneumococcal polysaccharide vaccine
Description: single intramuscular injection of 0.5 ml Pneumo23® (Sanofi-Aventis, Lyon France)